Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial
Thrombosis and Haemostasis · 2024-06 · 124 (06) · 517-527
DOI: 10.1055/a-2156-7872 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 11.09.2023. Verfasst von Yasushi Ueki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ticagrelor, Myocardial Infarction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: British Heart Foundation, Bern University Hospital.
Abstract (Originalsprache)
Objective
The effect of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab on platelet aggregation among patients with acute myocardial infarction (AMI) remains unknown. We aimed to explore the effect of alirocumab added to high-intensity statin therapy on P2Y12 reaction unit (PRU) among AMI patients receiving dual antiplatelet therapy (DAPT) with a potent P2Y12 inhibitor (ticagrelor or prasugrel). In addition, we assessed circulating platelet-derived noncoding RNAs (microRNAs and YRNAs).
Methods
This was a prespecified, powered, pharmacodynamic substudy of the PACMAN trial, a randomized, double-blind trial comparing biweekly alirocumab (150 mg) versus placebo in AMI patients undergoing percutaneous coronary intervention. Patients recruited at Bern University Hospital, receiving DAPT with a potent P2Y12 inhibitor, and adherent to the study drug (alirocumab or placebo) were analyzed for the current study. The primary endpoint was PRU at 4 weeks after study drug initiation as assessed by VerifyNow P2Y12 point-of-care assays.
Results
Among 139 randomized patients, the majority of patients received ticagrelor DAPT at 4 weeks (57 [86.4%] in the alirocumab group vs. 69 [94.5%] in the placebo group, p = 0.14). There were no significant differences in the primary endpoint PRU at 4 weeks between groups (12.5 [interquartile range, IQR: 27.0] vs. 19.0 [IQR: 30.0], p = 0.26). Consistent results were observed in 126 patients treated with ticagrelor (13.0 [IQR: 20.0] vs. 18.0 [IQR: 27.0], p = 0.28). Similarly, platelet-derived noncoding RNAs did not significantly differ between groups.
Conclusion
Among AMI patients receiving DAPT with a potent P2Y12 inhibitor, alirocumab had no significant effect on platelet reactivity as assessed by PRU and platelet-derived noncoding RNAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.
- CTU Bern, University of Bern, Bern, Switzerland.
- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
- Institute of Hospital Pharmacy, Bern University Hospital, Bern, Switzerland.
- Department of Pharmacology, Bern University, Bern and Sanofi, Switzerland.
- Cardiocentro Ticino, Institute and Università della Svizzera Italiana (USI), Lugano, Switzerland.
ORCID-Profile: Yasushi Ueki
Förderung
- British Heart Foundation
- Bern University Hospital
Zitieren
APA
Ueki, Y., Häner, J. D., Losdat, S., Gargiulo, G., Shibutani, H., Bär, S., Otsuka, T., Kavaliauskaite, R., Mitter, V. R., Temperli, F., Spirk, D., Stortecky, S., Siontis, G. C. M., Valgimigli, M., Windecker, S., Gutmann, C., Koskinas, K. C., Mayr, M., & Räber, L. (2024). Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial. Thrombosis and Haemostasis, 124(06), 517-527. https://doi.org/10.1055/a-2156-7872
Vancouver
Ueki Y, Häner JD, Losdat S, Gargiulo G, Shibutani H, Bär S, et al. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial. Thrombosis and Haemostasis. 2024;124(06):517-527. doi:10.1055/a-2156-7872
BibTeX
@article{Ueki2024,
author = {Ueki, Yasushi and Häner, Jonas D and Losdat, Sylvain and Gargiulo, Giuseppe and Shibutani, Hiroki and Bär, Sarah and Otsuka, Tatsuhiko and Kavaliauskaite, Raminta and Mitter, Vera R and Temperli, Fabrice and Spirk, David and Stortecky, Stefan and Siontis, George C M and Valgimigli, Marco and Windecker, Stephan and Gutmann, Clemens and Koskinas, Konstantinos C and Mayr, Manuel and Räber, Lorenz},
title = {Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial},
journal = {Thrombosis and Haemostasis},
year = {2024},
volume = {124},
number = {06},
pages = {517--527},
doi = {10.1055/a-2156-7872}
}
EUVIMED